A multicentre, open-label, phase III randomized trial supports the use of adjuvant gemcitabine in patients with advanced pancreatic cancer who undergo resection with curative intent. The median follow-up time for the 354 (of 368) patients included in the intention-to-treat analysis was 136 months. Compared with observation alone, adjuvant gemcitabine given for 6 months prolonged median disease-free survival and overall survival (measured at 5 and 10 years).
References
Oettle, H. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA 310, 1473–1481 (2013)
Rights and permissions
About this article
Cite this article
Adjuvant gemcitabine improves long-term outcomes of patients with resected pancreatic cancer. Nat Rev Gastroenterol Hepatol 10, 695 (2013). https://doi.org/10.1038/nrgastro.2013.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.209